Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
暂无分享,去创建一个
C. Gordon | K. Kalunian | M. Petri | V. Strand | D. Wallace | F. Houssiau | M. Pike | S. Bongardt | A. Barry | B. Kilgallen | L. Kelley